We are live on ! Find out more
PHAT icon

Phathom Pharmaceuticals
PHAT

84 hedge funds and large institutions have $820M invested in Phathom Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 22 increasing their positions, 23 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 8

6% more funds holding

Funds holding: 79 → 84 (+5)

1.91% more ownership

Funds ownership: 79.54% → 81.45% (+1.9%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

3% less capital invested

Capital invested by funds: $843M → $820M (-$23.3M)

4% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 23

Holders
84
Holders Change
+5
Holders Change %
+6.33%
% of All Funds
1.47%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
13
Increased
22
Reduced
23
Closed
8
Calls
$523K
Puts
–
Net Calls
+$523K
Net Calls Change
+$184K

Top Buyers

1
SG
StepStone Group
California
+$14M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$8.45M
3
GPP
Great Point Partners
Connecticut
+$7.34M
4
JP Morgan Chase
JP Morgan Chase
New York
+$5.21M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.12M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$2.03M
2
Ensign Peak Advisors
Ensign Peak Advisors
Utah
-$1.65M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$1.47M
4
MWNA
Marshall Wace North America
New York
-$1.17M
5
Marshall Wace
Marshall Wace
United Kingdom
-$1.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
PMAM
26
Penn Mutual Asset Management
Pennsylvania
$2.79M – – –
Adage Capital Partners
27
Adage Capital Partners
Massachusetts
$2.62M – – –
Jacobs Levy Equity Management
28
Jacobs Levy Equity Management
New Jersey
$2.28M -$1.47M -44,305 -38%
N
29
Nuveen
North Carolina
$2.23M -$814K -24,490 -26%
Bank of America
30
Bank of America
North Carolina
$2.07M +$32.9K +990 +2%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$1.87M +$243K +7,323 +14%
SEI Investments
32
SEI Investments
Pennsylvania
$1.38M +$117K +3,516 +9%
Dimensional Fund Advisors
33
Dimensional Fund Advisors
Texas
$1.26M +$1.31M +39,374 New
SRA
34
Summit Rock Advisors
New York
$1.09M – – –
PVI
35
Pura Vida Investments
New York
$1.05M -$420K -12,636 -28%
Swiss National Bank
36
Swiss National Bank
Switzerland
$995K – – –
WP
37
Woodline Partners
California
$960K +$994K +29,903 New
Morgan Stanley
38
Morgan Stanley
New York
$857K +$8.01K +241 +0.9%
CIP
39
Chartwell Investment Partners
Pennsylvania
$725K – – –
Two Sigma Investments
40
Two Sigma Investments
New York
$724K -$579K -17,429 -44%
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$721K -$182K -5,465 -20%
MAM
42
Martingale Asset Management
Massachusetts
$640K +$662K +19,908 New
Citadel Advisors
43
Citadel Advisors
Florida
$623K -$2.03M -60,964 -76%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$560K +$33.8K +1,016 +6%
Two Sigma Advisers
45
Two Sigma Advisers
New York
$526K -$302K -9,100 -36%
BFM
46
Boothbay Fund Management
New York
$479K +$1.03K +31 +0.2%
PP
47
PDT Partners
New York
$478K – – –
State of Wisconsin Investment Board
48
State of Wisconsin Investment Board
Wisconsin
$478K – – –
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$469K -$95.6K -2,878 -16%
PPA
50
Parametric Portfolio Associates
Washington
$438K +$453K +13,640 New
1
2
3 4

PHAT Hedge Fund Activity: Q3 2021 in Review

84 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q3 2021, worth a combined $820M — down 2.8% from $843M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new PHAT positions and 8 closed out — a net gain of 5 holders — while 22 added to existing stakes and 23 trimmed.

The largest buyer was StepStone Group, opening a new position worth an estimated $14M. The largest seller was Citadel Advisors, cutting an estimated $2.03M.

  • 84 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q3 2021, up from 79 in Q2 2021.
  • Funds reported $820M of Phathom Pharmaceuticals stock for Q3 2021, down 2.8% quarter-over-quarter.
  • 13 funds opened new Phathom Pharmaceuticals positions in Q3 2021 and 8 closed out, a net change of +5 holders.
  • The largest Phathom Pharmaceuticals buyer in Q3 2021 was StepStone Group, an estimated $14M added.
  • The largest Phathom Pharmaceuticals seller in Q3 2021 was Citadel Advisors, an estimated $2.03M sold.

Based on aggregated 13F filings for Q3 2021.